Amgen Inc. company and executive profile by Barron's. View the latest AMGN company infomation and executive bios.

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Indivior (INDV – Research Report) today and set a price target of $13.00. The company’s shares opened today at ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

The aquarium will be developed on a one-acre plot at an estimated cost of ₹50 crore. This special project will be carried out ...

Columbus City Schools receive $740K to launch hands-on manufacturing programs, preparing students for Ohio’s high-demand STEM ...

Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Patent claims reciting compounds where at least one group of a compound genus is defined by its function are common. For ...

Foundation joined Hydro One  and partners at I.E. Weldon Secondary School in Lindsay yesterday to mark the milestone of more ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...